Christensen, Louise N.
Novo Nordisk (Denmark)
3 papers on CoChat
Most cited papers
- Verified
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 868
- Verified
Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5
Wharton, S., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2023) · Obesity
Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity
Cited by 124
- Verified
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Christensen, L., Davies, M., Hovingh, K. G., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · JACC: Heart Failure
Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors
Cited by 97
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free